Total Payments
$7,312
2024 Payments
$92.82
Companies
15
Transactions
80
Medicare Patients
2,925
Medicare Billing
$423,996
Payment Breakdown by Category
Consulting$5,550 (75.9%)
Food & Beverage$1,315 (18.0%)
Education$446.70 (6.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,550 | 3 | 75.9% |
| Food and Beverage | $1,315 | 69 | 18.0% |
| Education | $446.70 | 8 | 6.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $5,575 | 4 | $0 (2022) |
| Celgene Corporation | $350.10 | 16 | $0 (2023) |
| PFIZER INC. | $309.04 | 18 | $0 (2022) |
| Astellas Pharma US Inc | $302.70 | 11 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $272.34 | 15 | $0 (2023) |
| Seagen Inc. | $168.94 | 2 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $94.99 | 2 | $0 (2021) |
| ADC Therapeutics America, Inc. | $61.91 | 1 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $54.01 | 4 | $0 (2020) |
| Gilead Sciences, Inc. | $36.80 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $92.82 | 3 | ADC Therapeutics America, Inc. ($61.91) |
| 2023 | $336.29 | 9 | Seagen Inc. ($168.94) |
| 2022 | $362.30 | 12 | Astellas Pharma US Inc ($173.48) |
| 2021 | $90.57 | 5 | E.R. Squibb & Sons, L.L.C. ($27.00) |
| 2020 | $694.48 | 7 | Merck Sharp & Dohme Corporation ($600.00) |
| 2019 | $395.36 | 20 | E.R. Squibb & Sons, L.L.C. ($88.33) |
| 2018 | $2,497 | 15 | Merck Sharp & Dohme Corporation ($2,250) |
| 2017 | $2,843 | 9 | Merck Sharp & Dohme Corporation ($2,700) |
All Payment Transactions
80 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/13/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Oncology | ||||||
| 05/01/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $61.91 | General |
| 01/25/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: Oncology | ||||||
| 12/14/2023 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Education | In-kind items and services | $21.31 | General |
| Category: Hematology | ||||||
| 10/19/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $31.97 | General |
| Category: Hematology | ||||||
| 10/13/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Oncology | ||||||
| 10/12/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Oncology | ||||||
| 06/08/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $30.35 | General |
| Category: Hematology | ||||||
| 04/04/2023 | Seagen Inc. | — | Education | In-kind items and services | $82.99 | General |
| 02/23/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.59 | General |
| Category: Hematology | ||||||
| 02/16/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: ONCOLOGY | ||||||
| 01/06/2023 | Seagen Inc. | — | Education | In-kind items and services | $85.95 | General |
| 12/20/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 12/20/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $57.99 | General |
| 12/14/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.44 | General |
| Category: Neuroscience | ||||||
| 12/09/2022 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2022 | Astellas Pharma US Inc | PADCEV (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Oncology | ||||||
| 09/21/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.25 | General |
| Category: Neuroscience | ||||||
| 08/25/2022 | PFIZER INC. | XTANDI (Drug), ORGOVYX, PAXLOVID | Food and Beverage | In-kind items and services | $26.16 | General |
| Category: ONCOLOGY | ||||||
| 07/14/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $24.35 | General |
| Category: Hematology | ||||||
| 06/09/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: ONC | ||||||
| 05/05/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: ONCOLOGY | ||||||
| 03/17/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $16.84 | General |
| Category: Hematology | ||||||
| 02/28/2022 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2021 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Education | In-kind items and services | $11.07 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 636 | 1,262 | $388,387 | $109,954 |
| 2022 | 7 | 603 | 1,202 | $361,235 | $108,119 |
| 2021 | 9 | 765 | 1,277 | $332,565 | $115,179 |
| 2020 | 12 | 921 | 1,346 | $291,132 | $90,745 |
Total Patients
2,925
Total Services
5,087
Medicare Billing
$423,996
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 306 | 733 | $247,727 | $68,250 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 91 | 165 | $72,585 | $22,689 | 31.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 144 | 218 | $50,390 | $13,881 | 27.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $12,960 | $3,305 | 25.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 12 | 15 | $3,165 | $956.67 | 30.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 56 | 104 | $1,560 | $873.60 | 56.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 312 | 787 | $251,935 | $75,427 | 29.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 154 | 227 | $50,385 | $14,829 | 29.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 55 | 82 | $34,680 | $10,550 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $11,475 | $3,226 | 28.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $6,100 | $2,086 | 34.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 18 | 20 | $5,925 | $1,856 | 31.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 27 | 49 | $735.00 | $145.53 | 19.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 294 | 681 | $205,230 | $70,678 | 34.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 153 | 198 | $40,805 | $14,324 | 35.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 70 | $26,428 | $10,512 | 39.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 58 | 75 | $20,625 | $7,602 | 36.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 83 | 94 | $16,826 | $5,253 | 31.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $7,581 | $2,279 | 30.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 20 | $5,980 | $2,267 | 37.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 65 | 66 | $8,250 | $2,095 | 25.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 24 | 56 | $840.00 | $168.00 | 20.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 246 | 504 | $132,586 | $40,079 | 30.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 212 | 294 | $52,626 | $18,000 | 34.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 132 | 155 | $27,520 | $8,464 | 30.8% |
About Dr. Kenneth Bishop, MD
Dr. Kenneth Bishop, MD is a Hematology & Oncology healthcare provider based in Attleboro, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1598925091.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Bishop, MD has received a total of $7,312 in payments from pharmaceutical and medical device companies, with $92.82 received in 2024. These payments were reported across 80 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($5,550).
As a Medicare-enrolled provider, Bishop has provided services to 2,925 Medicare beneficiaries, totaling 5,087 services with total Medicare billing of $423,996. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Attleboro, MA
- Active Since 06/10/2008
- Last Updated 07/31/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1598925091
Products in Payments
- GARDASIL (Biological) $5,550
- XTANDI (Drug) $253.76
- OPDIVO (Biological) $158.27
- Abraxane (Drug) $125.32
- REBLOZYL (Biological) $109.22
- IBRANCE (Drug) $79.37
- FASLODEX (Drug) $74.99
- MYRBETRIQ (Drug) $57.80
- BENDEKA (Drug) $54.01
- Pomalyst (Drug) $52.26
- Xtandi (Drug) $47.33
- ZEPOSIA (Drug) $40.69
- Trodelvy (Drug) $36.80
- Revlimid (Drug) $35.77
- KEYTRUDA (Biological) $24.60
- KRAZATI (Drug) $22.69
- LYNPARZA (Drug) $20.00
- ERLEADA (Drug) $19.02
- Imbruvica (Drug) $16.91
- PADCEV (Drug) $15.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.